Aldeyra details FDA talks on reproxalap NDA
Aldeyra Therapeutics, Inc. reports ongoing regulatory interactions with the U.S. Food and Drug Administration related to reproxalap for the treatment of dry eye disease.
Rhea-AI Filing Summary
Aldeyra Therapeutics, Inc. reports ongoing regulatory interactions with the U.S. Food and Drug Administration related to reproxalap for the treatment of dry eye disease. On July 14, 2026, Aldeyra received minutes from an FDA Type A meeting held on June 10, 2026, which addressed potential resubmission of the New Drug Application for reproxalap.
On July 15, 2026, Aldeyra requested clarification of the FDA’s meeting minutes and intends to request a Type D meeting with the FDA to further discuss potential NDA resubmission. The Type D meeting is expected to be held by the end of the third quarter of 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Type A meeting date: June 10, 2026
Minutes received date: July 14, 2026
Planned Type D meeting timing: end of the third quarter of 2026
3 metrics
Type A meeting date
June 10, 2026
Date of FDA Type A meeting on reproxalap NDA
Minutes received date
July 14, 2026
Date Aldeyra received FDA Type A meeting minutes
Planned Type D meeting timing
end of the third quarter of 2026
Expected timing for FDA Type D meeting on potential NDA resubmission
Key Terms
Type A meeting, Type D meeting, New Drug Application, dry eye disease
4 terms
Type A meeting regulatory
"received minutes from a Type A meeting, held on June 10, 2026 with the U.S."
A Type A meeting is an urgent, short-notice session requested between a company and a regulatory agency (for example, the FDA in the U.S.) to resolve critical issues that block a development program, such as a clinical hold or safety concern. Investors care because the outcome can immediately affect whether a clinical trial or approval process resumes, changing timelines, costs and the company’s near-term value — like calling an emergency mechanic when a car won’t start so a trip can continue.
Type D meeting regulatory
"intends to request a Type D meeting with the FDA to discuss"
New Drug Application regulatory
"potential resubmission of the New Drug Application (NDA) of reproxalap"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
dry eye disease medical
"New Drug Application (NDA) of reproxalap for the treatment of dry eye disease"
Dry eye disease is a chronic condition where the eyes do not make enough tears or the tears evaporate too quickly, causing irritation, blurred vision and sensitivity to light — imagine having tiny grains of sand or a windshield with streaks that never clear. It matters to investors because it creates steady demand for prescription drugs, medical devices and diagnostic tests; treatments can be long‑term, subject to regulatory approval and insurance coverage, and successful products can capture large, recurring revenue streams.
FAQ
What did Aldeyra Therapeutics (ALDX) disclose about its FDA interactions?
Aldeyra disclosed that it received FDA Type A meeting minutes on July 14, 2026 regarding potential resubmission of the reproxalap NDA for dry eye disease and plans a Type D meeting by the end of the third quarter of 2026.
What is reproxalap in Aldeyra Therapeutics (ALDX)'s latest update?
Reproxalap is described as a candidate for the treatment of dry eye disease. The recent disclosure centers on FDA regulatory discussions about the potential resubmission of its New Drug Application (NDA), rather than on clinical results or commercial launch details.
When did Aldeyra Therapeutics (ALDX) hold its FDA Type A meeting on reproxalap?
The FDA Type A meeting discussing potential resubmission of the reproxalap NDA was held on June 10, 2026. Aldeyra later received the formal minutes from this meeting on July 14, 2026, providing an official record of the discussion.
What follow-up steps is Aldeyra Therapeutics (ALDX) taking with the FDA?
Aldeyra requested clarification of the FDA’s Type A meeting minutes on July 15, 2026 and intends to seek a Type D meeting. That meeting is expected by the end of the third quarter of 2026 to continue NDA resubmission discussions.
Does Aldeyra Therapeutics (ALDX)'s update mention any FDA approval decision?
No approval decision is described; the disclosure focuses on regulatory dialogue about a potential resubmission of the reproxalap NDA. It details receipt and clarification of Type A meeting minutes and plans for a future Type D meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
